Epizyme Stock Forecast, Price & News

+0.15 (+1.68 %)
(As of 06/23/2021 02:03 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume12,715 shs
Average Volume1.04 million shs
Market Capitalization$927.98 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

Epizyme logo

About Epizyme

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.85 out of 5 stars

Medical Sector

162nd out of 2,105 stocks

Pharmaceutical Preparations Industry

73rd out of 832 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

Is Epizyme a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Epizyme stock.
View analyst ratings for Epizyme
or view top-rated stocks.

What stocks does MarketBeat like better than Epizyme?

Wall Street analysts have given Epizyme a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Epizyme wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Epizyme

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.13. The biopharmaceutical company had revenue of $7.60 million for the quarter, compared to the consensus estimate of $6.73 million. Epizyme had a negative net margin of 1,139.03% and a negative trailing twelve-month return on equity of 143.20%. The business's revenue for the quarter was up 442.9% compared to the same quarter last year.
View Epizyme's earnings history

How has Epizyme's stock been impacted by COVID-19 (Coronavirus)?

Epizyme's stock was trading at $18.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EPZM shares have decreased by 50.9% and is now trading at $9.06.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EPZM?

6 equities research analysts have issued 1 year target prices for Epizyme's shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Epizyme's share price to reach $16.33 in the next year. This suggests a possible upside of 80.3% from the stock's current price.
View analysts' price targets for Epizyme
or view top-rated stocks among Wall Street analysts.

Who are Epizyme's key executives?

Epizyme's management team includes the following people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 53, Pay $1.01M)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 57, Pay $628.41k)
  • Mr. Matthew E. Ros, Exec. VP and Chief Strategy & Bus. Officer (Age 54, Pay $644.06k)
  • Dr. Shefali Agarwal M.D., MPH, Exec. VP and Chief Medical & Devel. Officer (Age 47, Pay $737.27k)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 40)
  • Dr. Jeffery L. Kutok, Chief Scientific Officer (Age 54)
  • Jason Fredette, VP of Investor Relations
  • Mr. John F. Weidenbruch, Gen. Counsel (Age 60)

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (14.94%), Redmile Group LLC (8.65%), BlackRock Inc. (8.23%), Palo Alto Investors LP (6.72%), Rock Springs Capital Management LP (2.75%) and Morgan Stanley (1.84%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme

Which major investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Redmile Group LLC, Price T Rowe Associates Inc. MD, Allianz Asset Management GmbH, North Star Investment Management Corp., Credit Suisse AG, PDT Partners LLC, and Dimensional Fund Advisors LP. Company insiders that have sold Epizyme company stock in the last year include Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme
or view top insider-selling stocks.

Which major investors are buying Epizyme stock?

EPZM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Wellington Shields Capital Management LLC, Citigroup Inc., Hennion & Walsh Asset Management Inc., Wellington Shields & Co. LLC, Rock Springs Capital Management LP, and Rafferty Asset Management LLC. Company insiders that have bought Epizyme stock in the last two years include Carl Goldfischer, and David M Mott.
View insider buying and selling activity for Epizyme
or or view top insider-buying stocks.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $9.06.

How much money does Epizyme make?

Epizyme has a market capitalization of $923.90 million and generates $15.76 million in revenue each year. The biopharmaceutical company earns $-231,690,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Epizyme have?

Epizyme employs 304 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is

Where are Epizyme's headquarters?

Epizyme is headquartered at 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.